Lenvacent 10 mg contains Lenvatinib, a potent tyrosine kinase inhibitor (TKI) used in targeted cancer therapy. It selectively inhibits multiple receptor tyrosine kinases (RTKs) involved in tumor angiogenesis, tumor growth, and cancer progression, including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. By blocking these pathways, Lenvatinib reduces tumor vascularization and cell proliferation, making it effective in several advanced cancers.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Targeted Cancer Therapy
Multi-targeted receptor tyrosine kinase inhibitor

Indications

Lenvacent 10 mg is indicated for the treatment of:

1. Differentiated Thyroid Cancer (DTC): For patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory disease.

2. Renal Cell Carcinoma (RCC): In combination with Everolimus for advanced RCC after prior anti-angiogenic therapy.

3. Hepatocellular Carcinoma (HCC): First-line treatment of unresectable HCC.

4. Endometrial Carcinoma: In combination with Pembrolizumab for advanced disease that is not MSI-H or dMMR, after progression on prior systemic therapy and when curative surgery or radiation is not an option.

Pharmacology & Mechanism of Action

Lenvatinib inhibits multiple RTKs by binding to the ATP-binding site, blocking kinase activity and downstream signaling. Key actions include:

• Inhibition of VEGFR1-3 → reduces angiogenesis.

• Inhibition of FGFR1-4 → blocks tumor proliferation dependent on FGF signaling.

• Inhibition of PDGFRα, KIT, RET → impairs tumor growth and progression.

These effects lead to reduced tumor vascularization, slowed tumor growth, and induction of apoptosis in tumor cells.

Absorption & Distribution: Peak plasma concentrations occur 1–4 hours post-dose. Highly protein-bound (98–99%).

Metabolism & Elimination: Metabolized via CYP3A and aldehyde oxidase; ~64% excreted in feces and 25% in urine. Half-life ~28 hours.

Dosage & Administration

Oral administration, with or without food, once daily:

• DTC: 24 mg daily

• RCC: 18 mg daily (with 5 mg Everolimus)

• HCC: ≥60 kg → 12 mg daily; <60 kg → 8 mg daily

• Endometrial carcinoma: 20 mg daily (with Pembrolizumab 200 mg IV every 3 weeks)

Special Administration Instructions: Capsules may be swallowed whole or dissolved in 1 tablespoon of water or apple juice (stir 3 minutes, drink, rinse glass with 1 tbsp water).

Dose Adjustments: Required for severe renal or hepatic impairment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

• QT-prolonging drugs: Increased risk of arrhythmia; avoid coadministration.

• CYP3A modulators may alter lenvatinib plasma levels.

Contraindications

• Known hypersensitivity to lenvatinib or its components.

Side Effects

Common and serious adverse effects include:

• Hypertension, cardiac dysfunction, arterial thromboembolism

• Hepatotoxicity, renal impairment, proteinuria

• Gastrointestinal issues: diarrhea, fistula formation, perforation

• QT prolongation, hypocalcemia, hemorrhage, wound healing complications

• Reversible posterior leukoencephalopathy syndrome

• Thyroid dysfunction

Precautions & Warnings

• Blood pressure: Monitor regularly; manage hypertension promptly.

• Cardiac monitoring: Especially in patients with heart disease.

• Renal & hepatic monitoring: Dose modifications required if function declines.

• Pregnancy & lactation: Avoid; can cause fetal harm; discontinue breastfeeding.

• Surgery: Withhold prior to surgery; resume based on wound healing.

Pregnancy & Lactation

• Pregnancy Category D: Can cause embryo-fetal harm.

• Lactation: Should be discontinued due to risk of serious adverse reactions in infants.

Pediatric Use

Safety and efficacy not established. Dose modifications exist for severe renal or hepatic impairment in adults, but pediatric use is not recommended.

Storage

• Store below 30°C in a dry, light-protected area.

• Keep out of reach of children.